5-chloropyrazinamide has been researched along with isoniazid in 3 studies
| Studies (5-chloropyrazinamide) | Trials (5-chloropyrazinamide) | Recent Studies (post-2010) (5-chloropyrazinamide) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 14 | 0 | 7 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | 5-chloropyrazinamide (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ; Jacobs, WR; Ngo, SC; Sayahi, H; Welch, JT; Zimhony, O | 1 |
| Doležal, M; Kubíček, V; Kuneš, J; Paterová, P; Servusová, B; Vobicková, J; Zitko, J | 1 |
| Doležal, M; Kubíček, V; Kučera, R; Kuneš, J; Mandíková, J; Paterová, P; Servusová, B; Zitko, J | 1 |
3 other study(ies) available for 5-chloropyrazinamide and isoniazid
| Article | Year |
|---|---|
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
Topics: Bacterial Proteins; Cell-Free System; Fatty Acid Synthases; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Molecular Structure; Mycobacterium tuberculosis; NADP; Oxidation-Reduction; Pyrazinamide; Reproducibility of Results; Substrate Specificity | 2007 |
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
Topics: Amides; Anti-Bacterial Agents; Antitubercular Agents; Mycobacterium tuberculosis; Pyrazines; Structure-Activity Relationship | 2013 |
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antitubercular Agents; Crystallography; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2014 |